Announcement • Jun 30
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026 Announcement • Jun 05
Guangzhou Kingmed Diagnostics Group Co., Ltd., Annual General Meeting, Jun 29, 2026 Guangzhou Kingmed Diagnostics Group Co., Ltd., Annual General Meeting, Jun 29, 2026, at 14:00 China Standard Time. Reported Earnings • Apr 25
First quarter 2026 earnings: EPS and revenues miss analyst expectations First quarter 2026 results: EPS: CN¥0.09 (up from CN¥0.06 loss in 1Q 2025). Revenue: CN¥1.35b (down 7.9% from 1Q 2025). Net income: CN¥42.8m (up CN¥70.6m from 1Q 2025). Profit margin: 3.2% (up from net loss in 1Q 2025). Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 64%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Healthcare industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 84 percentage points per year, which is a significant difference in performance. Announcement • Apr 12
Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) announces an Equity Buyback for CNY 200 million worth of its shares. Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) announces a share repurchase program. Under the program, the company will repurchase up to CNY 200 million worth of its shares. The shares will be repurchased at a price not more than CNY 35 per share. The repurchased shares will be used for equity incentives. If the company fails to use the repurchased shares for the said purpose within 3 years after the completion of the program, the unused shares will be cancelled. The source of funds for this share repurchase is the company's own funds. The authorization will be valid for a period of 6 months. Announcement • Mar 30
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report Q1, 2026 Results on Apr 25, 2026 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 Announcement • Dec 26
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: CN¥0.011 (up from CN¥0.009 in 3Q 2024). Revenue: CN¥1.54b (down 11% from 3Q 2024). Net income: CN¥5.20m (up 24% from 3Q 2024). Profit margin: 0.3% (up from 0.2% in 3Q 2024). Revenue missed analyst estimates by 10.0%. Earnings per share (EPS) also missed analyst estimates by 92%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Healthcare industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 87 percentage points per year, which is a significant difference in performance. Price Target Changed • Oct 22
Price target increased by 10.0% to CN¥30.82 Up from CN¥28.02, the current price target is an average from 6 analysts. New target price is 8.9% above last closing price of CN¥28.31. Stock is down 26% over the past year. The company is forecast to post earnings per share of CN¥0.19 next year compared to a net loss per share of CN¥0.82 last year. Announcement • Sep 30
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Reported Earnings • Aug 26
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: CN¥0.12 loss per share (down from CN¥0.23 profit in 2Q 2024). Revenue: CN¥1.53b (down 25% from 2Q 2024). Net loss: CN¥57.0m (down 153% from profit in 2Q 2024). Revenue missed analyst estimates by 5.1%. Earnings per share (EPS) also missed analyst estimates by 71%. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Healthcare industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 82 percentage points per year, which is a significant difference in performance. Announcement • Jun 30
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 Announcement • May 19
Guangzhou Kingmed Diagnostics Group Co., Ltd., Annual General Meeting, Jun 09, 2025 Guangzhou Kingmed Diagnostics Group Co., Ltd., Annual General Meeting, Jun 09, 2025, at 14:30 China Standard Time. Location: No. 10, Luoxuan 3rd Road, International Bio Island, Guangzhou, Guangdong China Price Target Changed • Apr 29
Price target decreased by 14% to CN¥29.11 Down from CN¥33.94, the current price target is an average from 7 analysts. New target price is approximately in line with last closing price of CN¥28.95. Stock is down 25% over the past year. The company is forecast to post earnings per share of CN¥1.28 next year compared to a net loss per share of CN¥0.82 last year. Reported Earnings • Apr 27
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: CN¥0.06 loss per share (further deteriorated from CN¥0.04 loss in 1Q 2024). Revenue: CN¥1.47b (down 20% from 1Q 2024). Net loss: CN¥27.8m (loss widened 49% from 1Q 2024). Revenue missed analyst estimates by 18%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Healthcare industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance. Announcement • Mar 28
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025 New Risk • Mar 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (255% payout ratio). Share price has been volatile over the past 3 months (8.3% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Major Estimate Revision • Feb 08
Consensus EPS estimates fall by 18% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from CN¥0.70 to CN¥0.576. Revenue forecast unchanged from CN¥7.80b at last update. Net income forecast to grow 242% next year vs 32% growth forecast for Healthcare industry in China. Consensus price target of CN¥33.37 unchanged from last update. Share price rose 23% to CN¥30.09 over the past week. Announcement • Dec 27
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025 Major Estimate Revision • Nov 14
Consensus EPS estimates fall by 14% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from CN¥0.642 to CN¥0.553 per share. Revenue forecast steady at CN¥7.58b. Net income forecast to grow 259% next year vs 31% growth forecast for Healthcare industry in China. Consensus price target of CN¥33.37 unchanged from last update. Share price was steady at CN¥33.40 over the past week. Major Estimate Revision • Nov 06
Consensus EPS estimates fall by 31% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥8.27b to CN¥7.52b. EPS estimate also fell from CN¥0.971 per share to CN¥0.666 per share. Net income forecast to grow 309% next year vs 34% growth forecast for Healthcare industry in China. Consensus price target down from CN¥34.45 to CN¥33.37. Share price fell 14% to CN¥32.70 over the past week. Reported Earnings • Oct 31
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: CN¥0.009 (down from CN¥0.62 in 3Q 2023). Revenue: CN¥2.02b (flat on 3Q 2023). Net income: CN¥4.19m (down 99% from 3Q 2023). Profit margin: 0.2% (down from 15% in 3Q 2023). Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 96%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥33.58, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 15x in the Healthcare industry in China. Total loss to shareholders of 65% over the past three years. Major Estimate Revision • Sep 06
Consensus EPS estimates fall by 37% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥9.08b to CN¥8.23b. EPS estimate also fell from CN¥1.55 per share to CN¥0.972 per share. Net income forecast to grow 36% next year vs 29% growth forecast for Healthcare industry in China. Consensus price target down from CN¥33.78 to CN¥32.76. Share price was steady at CN¥27.74 over the past week. Buy Or Sell Opportunity • Sep 04
Now 21% overvalued Over the last 90 days, the stock has fallen 14% to CN¥27.18. The fair value is estimated to be CN¥22.43, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 12% over the last 3 years. Earnings per share has declined by 40%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 151% in the next 2 years. New Risk • Sep 02
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 20% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 92% Cash payout ratio: 146% Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.4% net profit margin). Reported Earnings • Aug 31
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Second quarter 2024 results: EPS: CN¥0.23 (down from CN¥0.29 in 2Q 2023). Revenue: CN¥2.04b (down 6.9% from 2Q 2023). Net income: CN¥108.3m (down 20% from 2Q 2023). Profit margin: 5.3% (down from 6.2% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 9.5%. Earnings per share (EPS) also missed analyst estimates by 4.2%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 40% per year whereas the company’s share price has fallen by 36% per year. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥30.79, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 14x in the Healthcare industry in China. Total loss to shareholders of 76% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥25.21 per share. Buy Or Sell Opportunity • Jul 31
Now 23% overvalued Over the last 90 days, the stock has fallen 24% to CN¥29.13. The fair value is estimated to be CN¥23.68, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 4.5% over the last 3 years. Earnings per share has declined by 29%. Revenue is forecast to grow by 35% in 2 years. Earnings are forecast to grow by 131% in the next 2 years. Valuation Update With 7 Day Price Move • Jul 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥29.24, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 14x in the Healthcare industry in China. Total loss to shareholders of 77% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.68 per share. Buy Or Sell Opportunity • Jul 11
Now 20% overvalued Over the last 90 days, the stock has fallen 37% to CN¥28.44. The fair value is estimated to be CN¥23.68, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 4.5% over the last 3 years. Earnings per share has declined by 29%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 131% in the next 2 years. Announcement • Jun 29
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024 Major Estimate Revision • May 21
Consensus EPS estimates increase by 27% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from CN¥1.62 to CN¥2.05. Revenue forecast steady at CN¥9.64b. Net income forecast to grow 88% next year vs 32% growth forecast for Healthcare industry in China. Consensus price target of CN¥69.20 unchanged from last update. Share price rose 6.6% to CN¥38.03 over the past week. Major Estimate Revision • May 03
Consensus EPS estimates fall by 40% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥10.3b to CN¥9.65b. EPS estimate also fell from CN¥2.55 per share to CN¥1.54 per share. Net income forecast to grow 86% next year vs 32% growth forecast for Healthcare industry in China. Consensus price target down from CN¥77.09 to CN¥71.03. Share price was steady at CN¥38.35 over the past week. Price Target Changed • May 01
Price target decreased by 7.9% to CN¥71.03 Down from CN¥77.09, the current price target is an average from 8 analysts. New target price is 85% above last closing price of CN¥38.35. Stock is down 53% over the past year. The company is forecast to post earnings per share of CN¥2.67 for next year compared to CN¥1.38 last year. Reported Earnings • Apr 27
First quarter 2024 earnings: EPS and revenues miss analyst expectations First quarter 2024 results: CN¥0.04 loss per share (down from CN¥0.32 profit in 1Q 2023). Revenue: CN¥1.84b (down 13% from 1Q 2023). Net loss: CN¥18.6m (down 113% from profit in 1Q 2023). Revenue missed analyst estimates by 24%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings. Announcement • Apr 27
Guangzhou Kingmed Diagnostics Group Co., Ltd., Annual General Meeting, May 20, 2024 Guangzhou Kingmed Diagnostics Group Co., Ltd., Annual General Meeting, May 20, 2024, at 14:30 China Standard Time. Location: No. 10, Luoxuan 3rd Road, Guangzhou International Bio Island, Guangzhou, Guangdong China Valuation Update With 7 Day Price Move • Apr 12
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥45.50, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 15x in the Healthcare industry in China. Total loss to shareholders of 64% over the past three years. Announcement • Mar 30
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Feb 07
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥64.79, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 18x in the Healthcare industry in China. Total loss to shareholders of 59% over the past three years. Announcement • Jan 22
Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) announces an Equity Buyback for CNY 100 million worth of its shares. Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The shares will be repurchased at a price not more than CNY 80 per share. The repurchased shares will be used for equity incentives. The source of funds for this share repurchase is the company's own funds. The authorization will be valid for a period of 12 months. Announcement • Dec 29
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024 Announcement • Dec 19
Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) announces an Equity Buyback for CNY 10 million worth of its shares. Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) announces a share repurchase program. Under the program, the company will repurchase up to CNY 10 million worth of its A shares. The shares will be repurchased at a price not more than CNY 80 per share. The repurchased shares will be used for equity incentives. The authorization will be valid for a period of 12 months. Reported Earnings • Nov 02
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2023 results: EPS: CN¥0.62 (down from CN¥1.72 in 3Q 2022). Revenue: CN¥2.00b (down 49% from 3Q 2022). Net income: CN¥291.2m (down 64% from 3Q 2022). Profit margin: 15% (down from 21% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 18%. Earnings per share (EPS) exceeded analyst estimates by 20%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥63.27, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 22x in the Healthcare industry in China. Total loss to shareholders of 39% over the past three years. Major Estimate Revision • Oct 30
Consensus EPS estimates increase by 12% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from CN¥1.75 to CN¥1.96. Revenue forecast unchanged at CN¥9.49b. Net income forecast to shrink 16% next year vs 27% growth forecast for Healthcare industry in China . Consensus price target of CN¥84.39 unchanged from last update. Share price rose 6.3% to CN¥61.04 over the past week. Announcement • Sep 21
Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) announces an Equity Buyback for CNY 50 million worth of its shares. Guangzhou Kingmed Diagnostics Group Co., Ltd. (SHSE:603882) announces a share repurchase program. Under the program, the company will repurchase up to CNY 50 million worth of its A shares. The shares will be repurchased at a price not more than CNY 75 per share. The purpose of repurchase program is implementing equity incentives. The source of fund for the repurchases will be company's own funds. The program will be valid for a period of 12 months. Price Target Changed • Sep 05
Price target decreased by 9.7% to CN¥86.89 Down from CN¥96.17, the current price target is an average from 8 analysts. New target price is 50% above last closing price of CN¥57.95. Stock is down 9.6% over the past year. The company is forecast to post earnings per share of CN¥1.73 for next year compared to CN¥5.90 last year. Major Estimate Revision • Sep 04
Consensus EPS estimates fall by 31% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from CN¥10.3b to CN¥9.79b. EPS estimate also fell from CN¥2.51 per share to CN¥1.73 per share. Net income forecast to shrink 17% next year vs 27% growth forecast for Healthcare industry in China . Consensus price target down from CN¥96.17 to CN¥91.51. Share price was steady at CN¥59.13 over the past week. Reported Earnings • Aug 29
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Second quarter 2023 results: EPS: CN¥0.29 (down from CN¥1.70 in 2Q 2022). Revenue: CN¥2.19b (down 46% from 2Q 2022). Net income: CN¥135.2m (down 83% from 2Q 2022). Profit margin: 6.2% (down from 20% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 16%. Earnings per share (EPS) also missed analyst estimates by 13%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. New Risk • Aug 29
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 12% Last year net profit margin: 19% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (114% cash payout ratio). Profit margins are more than 30% lower than last year (12% net profit margin). Announcement • Jun 28
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report first half, 2023 results on Aug 29, 2023 Reported Earnings • Apr 26
First quarter 2023 earnings: EPS and revenues miss analyst expectations First quarter 2023 results: EPS: CN¥0.32 (down from CN¥1.83 in 1Q 2022). Revenue: CN¥2.12b (down 50% from 1Q 2022). Net income: CN¥149.6m (down 82% from 1Q 2022). Profit margin: 7.1% (down from 20% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 17%. Earnings per share (EPS) also missed analyst estimates by 48%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). Deputy GM, Chief Brand Officer, Director of the President's Office & Director Linglai Wang was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 28
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: EPS: CN¥1.72 (up from CN¥1.30 in 3Q 2021). Revenue: CN¥3.90b (up 23% from 3Q 2021). Net income: CN¥805.4m (up 31% from 3Q 2021). Profit margin: 21% (up from 19% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 30%. Revenue is forecast to stay flat during the next 3 years compared to a 14% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥73.82, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Healthcare industry in China. Total returns to shareholders of 33% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥76.52 per share. Buying Opportunity • Oct 11
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 24%. The fair value is estimated to be CN¥76.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last 3 years. Earnings per share has grown by 63%. Revenue is forecast to decline by 5.3% in 2 years. Earnings is forecast to decline by 12% in the next 2 years. Buying Opportunity • Aug 24
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 16%. The fair value is estimated to be CN¥84.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last 3 years. Earnings per share has grown by 63%. Revenue is forecast to decline by 2.8% in 2 years. Earnings is forecast to decline by 11% in the next 2 years. Price Target Changed • Aug 21
Price target decreased to CN¥106 Down from CN¥116, the current price target is an average from 9 analysts. New target price is 57% above last closing price of CN¥67.47. Stock is down 41% over the past year. The company is forecast to post earnings per share of CN¥5.49 for next year compared to CN¥4.80 last year. Reported Earnings • Aug 19
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: EPS: CN¥1.70 (up from CN¥1.14 in 2Q 2021). Revenue: CN¥4.06b (up 46% from 2Q 2021). Net income: CN¥792.8m (up 52% from 2Q 2021). Profit margin: 20% (in line with 2Q 2021). Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) exceeded analyst estimates by 3.4%. Over the next year, revenue is expected to shrink by 4.4% compared to a 19% growth forecast for the Healthcare industry in China. Over the last 3 years on average, earnings per share has increased by 63% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improved over the past week After last week's 18% share price gain to CN¥81.33, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 17x in the Healthcare industry in China. Total returns to shareholders of 130% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥51.00 per share. Buying Opportunity • Apr 29
Now 21% undervalued Over the last 90 days, the stock is up 4.6%. The fair value is estimated to be CN¥103, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 36% over the last 3 years. Earnings per share has grown by 74%. For the next 3 years, revenue is forecast to grow by 5.1% per annum. Earnings is also forecast to grow by 4.4% per annum over the same time period. Price Target Changed • Apr 29
Price target decreased to CN¥126 Down from CN¥136, the current price target is an average from 8 analysts. New target price is 55% above last closing price of CN¥81.33. Stock is down 44% over the past year. The company is forecast to post earnings per share of CN¥4.74 for next year compared to CN¥4.80 last year. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: CN¥1.83 (up from CN¥1.16 in 1Q 2021). Revenue: CN¥4.25b (up 59% from 1Q 2021). Net income: CN¥850.2m (up 58% from 1Q 2021). Profit margin: 20% (in line with 1Q 2021). Revenue exceeded analyst estimates by 30%. Earnings per share (EPS) also surpassed analyst estimates by 35%. Over the next year, revenue is expected to shrink by 13% compared to a 23% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 69% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Non-Independent Director Linglai Wang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Price Target Changed • Apr 20
Price target decreased to CN¥136 Down from CN¥158, the current price target is an average from 8 analysts. New target price is 83% above last closing price of CN¥74.31. Stock is down 46% over the past year. The company is forecast to post earnings per share of CN¥4.45 for next year compared to CN¥3.29 last year. Price Target Changed • Nov 04
Price target decreased to CN¥171 Down from CN¥191, the current price target is an average from 9 analysts. New target price is 51% above last closing price of CN¥113. Stock is up 6.3% over the past year. The company is forecast to post earnings per share of CN¥4.49 for next year compared to CN¥3.29 last year. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥1.30 (vs CN¥1.09 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥3.16b (up 34% from 3Q 2020). Net income: CN¥613.0m (up 23% from 3Q 2020). Profit margin: 19% (down from 21% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 79% per year whereas the company’s share price has increased by 84% per year. Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment deteriorated over the past week After last week's 21% share price decline to CN¥108, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 15x in the Healthcare industry in China. Total returns to shareholders of 388% over the past three years. Reported Earnings • Aug 18
Second quarter 2021 earnings released: EPS CN¥1.14 (vs CN¥1.16 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: CN¥2.78b (up 21% from 2Q 2020). Net income: CN¥521.1m (up 2.6% from 2Q 2020). Profit margin: 19% (down from 22% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 83% per year whereas the company’s share price has increased by 80% per year. Valuation Update With 7 Day Price Move • Aug 03
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥151, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 15x in the Healthcare industry in China. Total returns to shareholders of 574% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥254 per share. Reported Earnings • Apr 20
First quarter 2021 earnings released: EPS CN¥1.16 (vs CN¥0.10 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.68b (up 129% from 1Q 2020). Net income: CN¥538.1m (up CN¥490.2m from 1Q 2020). Profit margin: 20% (up from 4.1% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has only increased by 70% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 24
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥138, the stock is trading at a trailing P/E ratio of 55.6x, down from the previous P/E ratio of 67.1x. This compares to an average P/E of 17x in the Healthcare industry in China. Total returns to shareholders over the past three years are 423%. Is New 90 Day High Low • Jan 21
New 90-day high: CN¥153 The company is up 42% from its price of CN¥108 on 23 October 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥138 per share. Valuation Update With 7 Day Price Move • Dec 31
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥128, the stock is trading at a trailing P/E ratio of 51.7x, up from the previous P/E ratio of 44.3x. This compares to an average P/E of 15x in the Healthcare industry in China. Total returns to shareholders over the past three years are 308%. Is New 90 Day High Low • Dec 25
New 90-day high: CN¥120 The company is up 20% from its price of CN¥99.84 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥138 per share. Is New 90 Day High Low • Nov 15
New 90-day low: CN¥86.20 The company is down 2.0% from its price of CN¥87.78 on 17 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥116 per share. Valuation Update With 7 Day Price Move • Nov 11
Market pulls back on stock over the past week After last week's 18% share price decline to CN¥87.64, the stock is trading at a trailing P/E ratio of 35.4x, down from the previous P/E ratio of 43.3x. This compares to an average P/E of 19x in the Healthcare industry in China. Total returns to shareholders over the past three years are 124%. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥1.14b, up 193% from the prior year. Total revenue was CN¥7.18b over the last 12 months, up 40% from the prior year. Is New 90 Day High Low • Oct 14
New 90-day high: CN¥117 The company is up 33% from its price of CN¥87.53 on 16 July 2020. The Chinese market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥20.94 per share. Announcement • Jul 08
Guangzhou Kingmed Diagnostics Group Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020 Guangzhou Kingmed Diagnostics Group Co., Ltd. announced that they will report first half, 2020 results on Aug 18, 2020 
